PH12022551223A1 - Adenosine receptor antagonist compounds - Google Patents

Adenosine receptor antagonist compounds

Info

Publication number
PH12022551223A1
PH12022551223A1 PH1/2022/551223A PH12022551223A PH12022551223A1 PH 12022551223 A1 PH12022551223 A1 PH 12022551223A1 PH 12022551223 A PH12022551223 A PH 12022551223A PH 12022551223 A1 PH12022551223 A1 PH 12022551223A1
Authority
PH
Philippines
Prior art keywords
compounds
compositions
adenosine receptor
receptor
receptor antagonist
Prior art date
Application number
PH1/2022/551223A
Other languages
English (en)
Inventor
Jun-Su Ban
Ju-Young Jung
Jeong-Ah Kim
Jeong-Geun Kim
Kyung-Sun Kim
Sung-Wook Kwon
Soo-Jin Lee
Yoon-Suk Lee
An-Na Moon
Sun-Young Park
Dong-Keun Song
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of PH12022551223A1 publication Critical patent/PH12022551223A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
PH1/2022/551223A 2019-11-19 2020-11-19 Adenosine receptor antagonist compounds PH12022551223A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190149117A KR20210061202A (ko) 2019-11-19 2019-11-19 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
PCT/IB2020/000971 WO2021099838A1 (en) 2019-11-19 2020-11-19 Adenosine receptor antagonist compounds

Publications (1)

Publication Number Publication Date
PH12022551223A1 true PH12022551223A1 (en) 2023-07-17

Family

ID=75980093

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/551223A PH12022551223A1 (en) 2019-11-19 2020-11-19 Adenosine receptor antagonist compounds

Country Status (14)

Country Link
US (1) US12606564B2 (https=)
EP (1) EP4061817A4 (https=)
JP (2) JP7681616B2 (https=)
KR (3) KR20210061202A (https=)
CN (2) CN116425756B (https=)
AU (2) AU2020386189B2 (https=)
BR (2) BR122023020015A2 (https=)
CA (1) CA3158731A1 (https=)
CL (1) CL2022001307A1 (https=)
IL (1) IL293107A (https=)
MX (1) MX2022005976A (https=)
PH (1) PH12022551223A1 (https=)
TW (3) TWI851336B (https=)
WO (3) WO2021099832A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806350B2 (en) 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
TW202508599A (zh) * 2023-05-19 2025-03-01 南韓商尹諾衛醫藥有限公司 用於神經保護或治療α突觸核蛋白及/或神經發炎相關疾病的化合物
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
KR20250123663A (ko) 2024-02-08 2025-08-18 아이리드비엠에스 주식회사 Cxcr7 수용체 조절제 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA971896B (en) * 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
EP0901476A4 (en) * 1996-03-26 2001-08-16 Du Pont Pharm Co PYRIDINES AND PYRIMIDINES FUSION ARYLOXY AND ARYLTHIO AND DERIVATIVES THEREOF
PL337888A1 (en) * 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
US6841549B1 (en) * 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100621D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
DK1444233T3 (da) 2001-11-09 2011-10-17 Gilead Palo Alto Inc A2B-adenosinreceptorantagonister
EP1615926A1 (en) * 2003-04-21 2006-01-18 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (purin-6-yl) amino acid and production method thereof
WO2008153947A2 (en) * 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011050160A1 (en) 2009-10-22 2011-04-28 Biogen Idec Ma Inc. Pharmaceuticals, compositions and methods of making and using the same
EA201890730A1 (ru) 2015-09-16 2018-10-31 Локсо Онколоджи, Инк. Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
DE102017125533A1 (de) 2017-10-31 2019-05-02 Helmholtz-Zentrum Dresden - Rossendorf E.V. 4-(Furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amin-Derivate und deren Verwendung
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
EP4061798B1 (en) 2019-11-19 2025-03-12 Clariant International Ltd Solvates of abscisic acid and liquid compositions containing abscisic acid
MX2022005914A (es) 2019-11-19 2022-08-04 Modag Gmbh Compuestos novedosos para el diagnostico, tratamiento y prevencion de enfermedades asociadas con la agregacion de alfa-sinucleina.
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders

Also Published As

Publication number Publication date
EP4061817A4 (en) 2023-11-01
TW202342481A (zh) 2023-11-01
KR20240148969A (ko) 2024-10-11
TWI851336B (zh) 2024-08-01
IL293107A (en) 2022-07-01
CN114829363B (zh) 2024-10-01
KR102752564B1 (ko) 2025-01-14
EP4061817A1 (en) 2022-09-28
WO2021099838A1 (en) 2021-05-27
WO2021099832A2 (en) 2021-05-27
KR102749480B1 (ko) 2025-01-07
CA3158731A1 (en) 2021-05-27
JP2023505915A (ja) 2023-02-13
MX2022005976A (es) 2022-08-18
TW202132304A (zh) 2021-09-01
CN114829363A (zh) 2022-07-29
AU2023202886A1 (en) 2023-05-25
WO2021099832A3 (en) 2021-07-01
CN116425756B (zh) 2025-05-13
BR122023020015A2 (pt) 2024-02-27
WO2021099838A9 (en) 2021-09-30
AU2020386189A1 (en) 2022-06-02
WO2021099838A8 (en) 2021-08-12
CL2022001307A1 (es) 2023-03-03
KR20220104760A (ko) 2022-07-26
WO2021099837A1 (en) 2021-05-27
TWI850492B (zh) 2024-08-01
TW202132305A (zh) 2021-09-01
CN116425756A (zh) 2023-07-14
US20230159534A1 (en) 2023-05-25
JP7681616B2 (ja) 2025-05-22
JP2025120182A (ja) 2025-08-15
US12606564B2 (en) 2026-04-21
AU2020386189B2 (en) 2024-05-16
KR20210061202A (ko) 2021-05-27
BR112022009487A2 (pt) 2023-02-23
AU2023202886B2 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
PH12022551223A1 (en) Adenosine receptor antagonist compounds
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
JOP20190151A1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
TN2010000040A1 (en) 2-3-7-substituted imidazo - [1-2b] pyridazines for treatment of alk 4 or alk 5 mediated diseases
WO2020252397A8 (en) Small molecule proteolysis-targeting chimeras and methods of use thereof
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
UA104849C2 (uk) 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
MX394094B (es) PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS.
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
EP4480543A3 (en) Chiral diaryl macrocycle and use thereof in the treatment of cancer
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
IL147271A0 (en) Compounds that bind her2
AU2016249140A8 (en) Anti-PACAP antibodies and uses thereof
MX388912B (es) Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos
MX2018012208A (es) Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
BR112018070586A8 (pt) Compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos
MY198880A (en) Phosphoramidate nucleoside derivatives as anticancer agents
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
CO2023007617A2 (es) Prevención y/o tratamiento de enfermedades del snc
PH12019502086A1 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2020061106A3 (en) Matter of composition, synthesis, formulation and application of fl118 platform positions 7 and 9-derived analogues for treatment of human disease